Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
83.51 USD | -0.87% | +3.49% | -13.39% |
Jun. 10 | Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion | DJ |
Jun. 10 | KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 | MT |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.26 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.39% | 15.86B | C | ||
+0.85% | 92.38B | A- | ||
-3.03% | 37.9B | A- | ||
-10.46% | 33.73B | B- | ||
+74.71% | 27.98B | A | ||
-1.08% | 13.97B | B- | ||
-11.15% | 11.67B | D+ | ||
+169.04% | 10.17B | D | ||
-50.19% | 10.04B | B | ||
+1.12% | 8.71B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BMRN Stock
- Ratings BioMarin Pharmaceutical Inc.